Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (20993)	4/21/1999 4:26:00 PM
From: RT	Respond to of 23519

VIVUS Announces First Quarter 1999 Earnings Per Share Company Expects To Report $0.12 EPS MOUNTAIN VIEW, Calif.--April 15, 1999--VIVUS, Inc. (Nasdaq: VVUS) today pre-announced that the Company expects to report $0.12 earnings per share for its first quarter 1999. Complete details of the Company quarterly results will be available via a press release to be issued on April 21, 1999, at the close of market. VIVUS invites all shareholders to participate in its conference call which will be held at 4:30 p.m. Eastern Time on April 21,1999. The call can be accessed via the Internet at www.vcall.com. VIVUS, Inc., is the developer and manufacturer of MUSE® (alprostadil) and ACTIS(TM), two advancements in the treatment of men with erectile dysfunction (''ED''), also known as impotence. The Company's objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders. The Company intends to market and sell its products through distribution, co-promotion or license agreements with corporate partners. Currently VIVUS markets MUSE and ACTIS in the United States and has retained its rights to market the products in Japan. Elsewhere around the globe, MUSE is partnered with ASTRAZENECA and Janssen Pharmaceutica through licensing and distribution agreements. VIVUS has active research, development and clinical programs, and it is currently conducting Phase III clinical trials for ALIBRA, its second-generation male ED treatment. Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). -------------------------------------------------------------------------------- Contact: VIVUS, Inc. Nina W. Ferrari, 650/934-5200 IR@VIVUS.com Please send comments and questions to webmaster@vcall.com Learn more about Vcall. © 1998 Vcall. All rights reserved. By using the Vcall web site, you have read and agreed to the Terms and Conditions of the site.